Matches in SemOpenAlex for { <https://semopenalex.org/work/W2965221684> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2965221684 abstract "e15502 Background: mUC is a chemotherapy sensitive tumor. Currently, CGP and MVAC are the most active regimens in this setting. According to Norton and Simon hypothesis, the administration of two sequential non cross-resistant, dose-dense chemotherapy regimens may target different cancer cells, avoid drug resistance, improve response rate and CR. Methods: Patients with histological diagnosis of mUC, PS 0–2 (ECOG), adequate organ function and no previous systemic regimens were treated with 4 cycles of CGP dose-dense (Gemcitabine 1000 mg/m2 d 1, Paclitaxel 140 mg/m2 d 1, Cisplatin 70 mg/m2 d 2 plus PegFilgrastim 6 mg on day 3, every 2 weeks) followed by 4 cycles of M-VAC (Methotrexate 30 mg/m2 d 1,Vinblastine 3 mg/m2 d 2, Doxorubicin 30 mg/m2 d 2, Cisplatin 70 mg/m2 d 2 plus Pegfilgrastim 6 mg on day 3 every 2 weeks). All were evaluated with CT scan at the baseline, after 4 cycles, at the end of chemotherapy and then every 3 months for two years and 6 months thereafter. Metastatic sites included retroperitoneal nodes, lung, liver and bone. Results: From January 2007, 35 consecutive pts followed in the same oncology institution were included. Male were 74%; median age 65 years; median PS ECOG was 1; Bajorin risk factors was 0 in 37%, 1 in 43%, 2 in 20%. All pts were hospitalized for three days and received chemotherapy with hydration and supportive therapy. After the first 4 cycles of CGP we observed 14.3% CR, 48.6% PR, 22.9% SD and 14.3% PD. After the 4 sequential cycles of M-VAC we observed a global 37.1% of CR, 25.7% of PR, 8.6% of SD and 28.6% of PD. Median TTP was 9.9 months ( 95 % CI, 7.53-14.83) and median OS was 24.27 months ( 95 % CI, 10.03-38.43). Main grade 3–4 toxicity included asthenia ( 27%), anemia (21%), neutropenia (12 %), febrile (9%), thrombocytopenia (9%) and peripheral neuropathy (6 %). After a median follow up of 33 months, 6 of 13 patients who obtained a complete response are free of disease. Conclusions: These data confirm that the sequential use of this two dose-dense regimens is very active and 17 % of patients maintained a CR status." @default.
- W2965221684 created "2019-08-13" @default.
- W2965221684 creator A5007804854 @default.
- W2965221684 creator A5010090619 @default.
- W2965221684 creator A5013554030 @default.
- W2965221684 creator A5023171492 @default.
- W2965221684 creator A5024850296 @default.
- W2965221684 creator A5039987253 @default.
- W2965221684 creator A5040541120 @default.
- W2965221684 creator A5050668592 @default.
- W2965221684 creator A5051036310 @default.
- W2965221684 creator A5053400405 @default.
- W2965221684 creator A5059407155 @default.
- W2965221684 creator A5066971975 @default.
- W2965221684 creator A5067193136 @default.
- W2965221684 creator A5069893430 @default.
- W2965221684 creator A5083123006 @default.
- W2965221684 creator A5084034066 @default.
- W2965221684 creator A5087655805 @default.
- W2965221684 date "2013-05-20" @default.
- W2965221684 modified "2023-09-27" @default.
- W2965221684 title "Rate of durable complete remission (CR) using two sequential, dose-dense regimens of cisplatin, gemcitabine, paclitaxel (CGP) followed by m-VAC in patients with metastatic urothelial cancer (mUC)." @default.
- W2965221684 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.e15502" @default.
- W2965221684 hasPublicationYear "2013" @default.
- W2965221684 type Work @default.
- W2965221684 sameAs 2965221684 @default.
- W2965221684 citedByCount "0" @default.
- W2965221684 crossrefType "journal-article" @default.
- W2965221684 hasAuthorship W2965221684A5007804854 @default.
- W2965221684 hasAuthorship W2965221684A5010090619 @default.
- W2965221684 hasAuthorship W2965221684A5013554030 @default.
- W2965221684 hasAuthorship W2965221684A5023171492 @default.
- W2965221684 hasAuthorship W2965221684A5024850296 @default.
- W2965221684 hasAuthorship W2965221684A5039987253 @default.
- W2965221684 hasAuthorship W2965221684A5040541120 @default.
- W2965221684 hasAuthorship W2965221684A5050668592 @default.
- W2965221684 hasAuthorship W2965221684A5051036310 @default.
- W2965221684 hasAuthorship W2965221684A5053400405 @default.
- W2965221684 hasAuthorship W2965221684A5059407155 @default.
- W2965221684 hasAuthorship W2965221684A5066971975 @default.
- W2965221684 hasAuthorship W2965221684A5067193136 @default.
- W2965221684 hasAuthorship W2965221684A5069893430 @default.
- W2965221684 hasAuthorship W2965221684A5083123006 @default.
- W2965221684 hasAuthorship W2965221684A5084034066 @default.
- W2965221684 hasAuthorship W2965221684A5087655805 @default.
- W2965221684 hasConcept C121608353 @default.
- W2965221684 hasConcept C126322002 @default.
- W2965221684 hasConcept C143998085 @default.
- W2965221684 hasConcept C2776694085 @default.
- W2965221684 hasConcept C2777292972 @default.
- W2965221684 hasConcept C2778239845 @default.
- W2965221684 hasConcept C2780258809 @default.
- W2965221684 hasConcept C2780352672 @default.
- W2965221684 hasConcept C3020745361 @default.
- W2965221684 hasConcept C71924100 @default.
- W2965221684 hasConceptScore W2965221684C121608353 @default.
- W2965221684 hasConceptScore W2965221684C126322002 @default.
- W2965221684 hasConceptScore W2965221684C143998085 @default.
- W2965221684 hasConceptScore W2965221684C2776694085 @default.
- W2965221684 hasConceptScore W2965221684C2777292972 @default.
- W2965221684 hasConceptScore W2965221684C2778239845 @default.
- W2965221684 hasConceptScore W2965221684C2780258809 @default.
- W2965221684 hasConceptScore W2965221684C2780352672 @default.
- W2965221684 hasConceptScore W2965221684C3020745361 @default.
- W2965221684 hasConceptScore W2965221684C71924100 @default.
- W2965221684 hasLocation W29652216841 @default.
- W2965221684 hasOpenAccess W2965221684 @default.
- W2965221684 hasPrimaryLocation W29652216841 @default.
- W2965221684 isParatext "false" @default.
- W2965221684 isRetracted "false" @default.
- W2965221684 magId "2965221684" @default.
- W2965221684 workType "article" @default.